β-Lactams enhance vancomycin activity against methicillin-Resistant staphylococcus aureus bacteremia compared to vancomycin alone

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 102-109

  Dilworth, Thomas J ^a   Ibrahim, Omar ^a   Hall, Pamela ^a   Sliwinski, Jora ^a   Walraven, Carla ^b   Mercier, Renée Claude ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; IMIPENEM; MEROPENEM; NAFCILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ERADICATION THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMS; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84891510686     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01204-13     Document Type: Article

References (45)

1. Chu VH, Crosslin DR, Friedman JY, Reed SD, Cabell CH, Griffiths RI, Masselink LE, Kaye KS, Corey GR, Reller LB, Stryjewski ME, Schulman KA, Fowler VG, Jr. 2005. Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes. Am. J. Med. 118:1416. http://dx.doi.org/10.1016/j. amjmed.2005.06.011
2. Cosgrove E, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. 2003. Comparison of mortality associated with methicillinresistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 36:53-59. http://dx.doi.org/10.1086/345476
3. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati R, Townes JM. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. http://dx.doi.org/10.1001/jama.298.15.1763
4. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55. http://dx.doi.org/10.1093/cid/ciq146
5. Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh M, Choe KW. 2008. Outcome of vancomycin treatment in patients with methicillinsusceptible Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 52:192-197. http://dx.doi.org/10.1128/AAC.00700-07
6. Stryjewski ME, Szczech LA, Benjamin DK, Inrig JK, Kanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller LB, Corey GR. 2007. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin. Infect. Dis. 44:190-196. http://dx.doi.org/10.1086/510386
7. Boucher HW, Sakoulas G. 2007. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 45:601-608. http://dx.doi.org/10.1086/520655
8. Welsh KJ, Skrobarcek KA, Abbott AN, Lewis CT, Kruzel MC, Lewis EM, Gardiner JM, Mohr JF, Armitige LY, Wanger A. 2011. Predictors of relapse of methicillin-resistant Staphylococcus aureus bacteremia after treatment with vancomycin. J. Clin. Microbiol. 49:3669-3672. http://dx.doi.org/10.1128/JCM. 05287-11
9. Kollef MH. 2007. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin. Infect. Dis. 45:S191-S195. http://dx.doi.org/10.1086/519470
10. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Jr, Eliopoulos GM. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402. http://dx.doi.org/10.1128/JCM.42. 6.2398-2402.2004
11. Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP. 2012. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 56:202-207. http://dx.doi.org/10.1128/AAC.05473-11
12. Leonard SN. 2012. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic Model. PLoS One 7:e42103. http://dx.doi.org/10.1371/journal.pone.0042103
13. Palmer SM, Rybak MJ. 1997. An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots. J. Antimicrob. Chemother. 39:515-518. http://dx.doi.org/10.1093/jac/39.4.515
14. Dilworth TJ, Sliwinski-Heath J, Ryan K, Dodd M, Mercier RC. 2012. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr E-1472
15. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R. 2008. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 34:17-60. http://dx.doi.org/10.1007/s00134-007-0934-2
16. Niederman M, Craven D, Bonten M, Chastre J, Craig W, Fagon J, Hall J, Jacoby G, Kollef M, Luna C. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416. http://dx.doi.org/10.1164/rccm. 200405-644ST
17. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. 2007. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev. Med. 45:247-251. http://dx.doi.org/10.1016/j.ypmed.2007.08.012
18. Chow JW, Yu VL. 1999. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int. J. Antimicrob. Agents. 11:7-12. http://dx.doi.org/10.1016/S0924-8579(98)00060-0
19. BioMerieux. 2009. Etest for MIC determination (package insert). BioMerieux, Inc., Solna, Sweden
20. Sakoulas G, Eliopoulos GM, Moellering RC, Wennersten C, Venkataraman L, Novick RP, Gold HS. 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492- 1502. http://dx.doi.org/10. 1128/AAC.46.5.1492-1502.2002
21. Francois P, Koessler T, Huyghe A, Harbarth S, Bento S, Lew D, Etienne J, Pittet D, Schrenzel J. 2006. Rapid Staphylococcus aureus agr type determination by a novel multiplex real-time quantitative PCR assay J. Clin. Microbiol. 44:1892-1895. http://dx.doi.org/10.1128/JCM.44.5.1892-1895.2006
22. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. 2003. Pulsed-field gel electrophoresis typing of oxacillinresistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120. http://dx.doi.org/10.1128/JCM.41.11. 5113-5120.2003
23. Firth D. 1993. Bias reduction of maximum likelihood estimates. Biometrika 80:27-38. http://dx.doi.org/10.1093/biomet/80.1.27
24. Heinze G, Schemper M. 2002. A solution to the problem of separation in logistic regression. Stat. Med. 21:2409-2419. http://dx.doi.org/10.1002/sim.1047
25. Fernández-Hidalgo N, Almirante B, Gavaldà J, Gurgui M, Peña C, de Alarcón A, Ruiz J, Vilacosta I, Montejo M, Vallejo N. 2013. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin. Infect. Dis. 56:1261- 1268. http://dx.doi.org/10.1093/cid/cit052
26. Stanley SK, Kaplan JE, Fauci A, Gordin F, Bartlett J, Goosby E, Harrington DM, Smith M, Chang S, Anderson J. 1998. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Recommend. Rep. 47(RR5):43- 82
27. Blumberg HM, Leonard MK, Jr, Jasmer RM. 2005. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 293: 2776-2784. http://dx.doi.org/10.1001/jama.293.22.2776
28. Hellwig T, Hammerquist R, Loecker B, Shields J. 2011. 301: Retrospective evaluation of the incidence of vancomycin and/or piperacillintazobactam induced acute renal failure. Crit. Care Med. 39(Suppl 12):79
29. Min E, Box K, Lane J, Sanchez J, Coimbra R, Doucet J, Potenza B, Wargel L. 2011. 714: Acute kidney injury in patients receiving concomitant vancomycin and piperacillin/tazobactam. Crit. Care Med. 39(Suppl 12):200
30. Lowy FD. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532. http://dx.doi.org/10.1056/NEJM199808203390806
31. Moise PA, Forrest A, Bayer AS, Yan Q. 2010. Xiong YQ, Yeaman MR, George Sakoulas G. 2010. Factors influencing time to vancomycininduced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes J. Infect. Dis. 201:233-240. http://dx.doi.org/10.1086/649429
32. Hawkins C, Huang J, Jin N, Noskin GA, Zembower TR, Bolon M. 2007. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch. Intern. Med. 167:1861. http://dx.doi.org/10.1001/archinte.167. 17.1861
33. Levine DP, Fromm BS, Reddy BR. 1991. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 115:674. http://dx.doi.org/10.7326/0003 -4819-115-9-674
34. Markowitz N, Quinn EL, Saravolatz LD. 1992. Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Intern. Med. 117:390. http://dx.doi.org/10.7326/0003-4819-117-5-390
35. Roder BL, Wandall DA, Frimodt-Moller N, Espersen F, Skinhoj P, Rosdahl VT. 1999. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch. Intern. Med. 159:462. http://dx.doi.org/10.1001/ archinte.159.5.462
36. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. 2011. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 66:2386-2392. http://dx.doi.org/10.1093/jac/dkr301
37. Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A. 2013. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment: a multicenter evaluation. Antimicrob. Agents Chemother. 57:1192-1200. http://dx.doi.org/10.1128/AAC.02192-12
38. Brown J, Brown K, Forrest A. 2012. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob. Agents Chemother. 56:634-638. http://dx.doi.org/10.1128/AAC.05609-11
39. Pastagia M, Kleinman LC, Lacerda de la Cruz EC, Jenkins SG. 2012. Predicting risk for death from MRSA bacteremia. Emerg. Infect. Dis. 18: 1072-1080. http://dx.doi.org/10.3201/eid1807.101371
40. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. 2011. Use of antistaphylococcal β-Lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillinresistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin. Infect. Dis. 53:158-163. http://dx.doi.org/10.1093/cid/cir340
41. Yang SJ, Xiong YQ, Boyle-Vavra S, Daum R, Jones T, Bayer AS. 2010. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillinresistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob. Agents Chemother. 54:3161-3169. http://dx.doi.org/10. 1128/AAC.00487-10
42. Werth BJ, Vidaillac C, Murray KP, Newton KL, Sakoulas G, Nonejuie P, Pogliano J, Rybak MJ. 2013. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycinintermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob. Agents Chemother. 57:2376-2379. http://dx.doi.org/10.1128/AAC.02354-12
43. Sieradzki K, Tomasz A. 1997. Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J. Antimicrob. Chemother. 39:47-51. http://dx.doi.org/10.1093/jac/39.suppl-1.47
44. Dilworth TJ, Leonard S, Mercier RC. 2013. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-023
45. Richter SS, Satola SW, Crispell EK, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Diekema DJ, Doern GV. 2011. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States. J. Clin. Microbiol. 49:4203-4207. http://dx.doi.org/10.1128/JCM. 01152-11